الفهرس 
General introduction
FormulationsOnly 14 pages are availabe for public view
 |  | from | 398 |  |  |
| | | from | 398 | | |
Abstract
Tinidazole was formulated in different bioadhesive vaginal dosage forms like gels, suppositories, and tablets using different mucoadhesive polymers. The effect of certain enhancers on the invitro release of the drug from the prepared gels was studied. The enhanceres used were tween 80, taurocholic acid, and transcutol at different concentrations. For the bioadhesive suppositories, different supppository bases containing different concentrations of bioadhesive polymers were used. For the vaginal tablets, lactose containing different concentrations of different polymers was used as a vehicle. Selected formulations were studied for the effect of storage at rom temperature for six months and evaluated clinicaly for their efficiency in the treatment ofTrichomonas vaginalis. Results indicate that, cellulose drivative polymers showed the highest drug release rate. Of the tested enhancers, 5% transcutol was the most efficient in enhancing the drug release from all gels except carbopol 934 which showed the maximum enhancement with 7% transcutol. For the mucoadhesive suppositories, the highest release rate of tinidazole was obtained with witepsol H15 containing 5% tween 80 and 2% sodium alginate. While the release of tinidazole from the bioadhesive tablets was found to be dependent on the polymer concentration . At the same polymer concentratin, the releaseretarding effect of carbopol 934 was the highest followed by carboxymethylcellulose sodium and lastly hydroxypropylmethylcellulose. Theselected formulae showed good stability for six months. The clinical study revealed that the highest percentages of the cured cases were obtained with vaginal suppositories formulated with polyethylene glycols containing 2% hydroxyethylcellulose and that formulated with witepsl H15 containing 2% sodium alginate and mucogel formulated with carbopol 934 containing 7% transcutol, all these formulations gave not less than 90% of cured cases. The statistical analyesis proved significant difference between these formulations and the commercial metronidazle avaliable in the Egyptian market in the treatment of Trichomonas vaginalis.